Welcome to our dedicated page for Lexicon Pharmaceuticals SEC filings (Ticker: LXRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Locating clinical trial details, royalty milestones, or INPEFA® sales data inside Lexicon Pharmaceuticals’ 200-page reports can feel like its own research project. Biotech disclosures mix dense scientific tables with SEC jargon, and Lexicon Pharmaceuticals insider trading Form 4 transactions often arrive just as new study results hit the wire.
Stock Titan solves the puzzle. Our AI breaks each Lexicon Pharmaceuticals quarterly earnings report 10-Q filing, 8-K update, or proxy into concise, plain-English briefs. Need to spot dose-response outcomes in seconds? Curious how R&D spending shifted before Phase 3? You’ll find answers in our real-time dashboard, along with alerts for Lexicon Pharmaceuticals Form 4 insider transactions real-time. We cover every document type—10-K, 10-Q, 8-K, S-3, DEF 14A—linking them to natural questions investors ask, like “What does Lexicon disclose about LX9211’s safety profile?” or “How is executive compensation tied to FDA milestones?”.
Dive deeper with context you won’t get from EDGAR alone. Our summaries flag where the Lexicon Pharmaceuticals annual report 10-K simplified explains Genome5000™ costs, highlight each Lexicon Pharmaceuticals proxy statement executive compensation table, and translate risk-factor language into actionable insights. Follow Lexicon Pharmaceuticals earnings report filing analysis quarter over quarter, track Lexicon Pharmaceuticals executive stock transactions Form 4, and view every Lexicon Pharmaceuticals 8-K material events explained—all through one interface. If you’re serious about understanding Lexicon Pharmaceuticals SEC documents with AI-assisted clarity, this is your starting line.
Lexicon Pharmaceuticals (LXRX) filed a prospectus supplement tied to its Open Market Sale Agreement with Jefferies, covering potential at‑the‑market sales of common stock with an aggregate sales price of up to $75,000,000 under its effective Form S‑3 shelf. The supplement relates to the shelf registration filed on August 2, 2024 and declared effective on August 15, 2024.
The company also corrected an inadvertent statement in the supplement that suggested Ernst & Young LLP audited the effectiveness of internal control over financial reporting as of December 31, 2024. As a smaller reporting company and non‑accelerated filer, Lexicon is exempt from that requirement, and EY did not perform such an audit. The notice does not constitute an offer or solicitation in jurisdictions where it would be unlawful.
Lexicon Pharmaceuticals launched an at-the-market offering of up to $75,000,000 of common stock through Jefferies as sales agent. No sales have been made to date. Jefferies will receive a 3.0% commission on gross proceeds, and net proceeds will be used to fund research and development and for working capital and general corporate purposes.
An affiliate of Invus, L.P., the company’s largest stockholder, may concurrently purchase shares to maintain its proportionate ownership in connection with sales under the program, but only after yearly issuances under the ATM exceed two percent of shares outstanding as of the prior December 31. Any such purchases would occur in a concurrent private placement at the same price as the public sales.
The common stock trades on Nasdaq as “LXRX.” The last reported sale price was $1.38 per share on November 5, 2025. Shares outstanding were 363,398,860 as of November 5, 2025; this is a baseline figure, not the amount being offered.
Lexicon Pharmaceuticals (LXRX) filed a prospectus supplement for an at-the-market (ATM) offering of up to $75,000,000 of common stock under its existing Form S-3, with Jefferies LLC as sales agent. The Shares may be offered and sold from time to time pursuant to the Open Market Sale Agreement.
As of November 6, 2025, no sales have been made pursuant to the Agreement. Vinson & Elkins L.L.P. provided a legal opinion on the validity of the Shares, filed as Exhibit 5.1.
Lexicon Pharmaceuticals (LXRX) filed its Q3 2025 10‑Q, reporting total revenues of $14.2 million, driven largely by $13.2 million in licensing revenue from its Novo Nordisk agreement. Net product revenue from INPEFA® was $1.0 million. The company posted a net loss of $12.8 million, a substantial improvement from a loss of $64.8 million a year ago, as operating expenses fell sharply following late‑2024 restructuring.
Cash, cash equivalents, restricted cash and short‑term investments totaled $145.0 million as of September 30, 2025, including $29.0 million in restricted cash tied to debt covenants. Lexicon repaid $45.0 million on its Oxford term loans in April, leaving $56.5 million in long‑term debt (carrying value) and a weighted average interest rate of 11.8%. The Novo Nordisk license delivered $40.7 million in year‑to‑date licensing revenue; $4.3 million of the $45.0 million upfront remained as deferred revenue at quarter‑end. The company maintains a $75 million at‑the‑market equity program available.
Lexicon Pharmaceuticals (LXRX) has resolved its Nasdaq listing deficiency. On 23 Jul 2025 the company received written notice from Nasdaq Listing Qualifications confirming that LXRX’s common stock has maintained a closing bid price at or above the $1.00 threshold long enough to regain full compliance with Rule 5550(a)(2). As a result, the prior non-compliance matter is formally closed and no further action is required by the company.
The 8-K contains no financial performance data, operational updates, or strategic announcements; its sole purpose is to inform investors that the risk of delisting has been removed. Regaining compliance preserves LXRX’s access to the Nasdaq Global Select Market, supporting share liquidity and investor confidence.
FAQ
What is the current stock price of Lexicon Pharmaceuticals (LXRX)?
What is the market cap of Lexicon Pharmaceuticals (LXRX)?
